You are here
Rimonabant NDA Withdrawn From FDA Consideration
Sanofi-aventis is confident in the positive benefit risk ratio of rimonabant 20mg when used in the appropriate population.
Sanofi-aventis will work toward submitting the rimonabant file to the FDA - Food and Drug Administration - at a future date. It will undertake the necessary discussions with the FDA to determine the required modifications to its file.
Sanofi-aventis is committed to taking all steps necessary to make rimonabant available to patients in the US market.
Rimonabant is a first in class therapy, discovered and developed by sanofi-aventis, is currently approved in 42 countries and marketed in 20 to treat obesity and overweight patients with associated cardiovascular risk factors.